Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Urinary Biomarker Found for Prostate Cancer Risk

By LabMedica International staff writers
Posted on 02 Nov 2010
A protein in urine could be a reliable marker for prostate cancer assessment and has advantages over the standard prostate specific antigen (PSA) test. More...


The protein, microseminoprotein-beta (MSMB), which is produced by normal prostate cells and secreted into urine from semen, regulates cell apoptosis or programmed cell death and is linked to an increased risk of developing prostate cancer.

In a multi-institute collaborative study, led by scientists from the Institute of Cancer Research, (CRUK; Cambridge, UK), tissue, urine and blood samples were analyzed from cohorts of prostate cancer patients. Urinary PSA and MSMB levels were determined by enzyme-linked immunoassays (ELISA) and normalized to creatinine. Samples from 133 of the patients were made into a tissue microarrays (TMA) containing multiple cores from normal/benign regions (>3), prostatic intraepithelial neoplasia (PIN) and at least two distinct regions of tumor for each patient. Genotyping was performed on DNA extracted from blood samples.

The urinary levels of MSMB were determined in 215 men with no history of prostate disease and 89 men with prostate cancer. Consistent with the association in prostate tissue there was a significant decrease in urinary MSMB in men with tumors compared with men with no history of prostate disease. No normal or tumorigenic tissues demonstrated any MSMB staining suggesting that at the protein level in tissue MSMB is highly prostate specific. In particular the tissues surrounding the prostate, such as urothelium, seminal vesicles and bladder muscularis propria layer showed no staining whereas adjacent benign prostate glands were heavily stained. MSMB demonstrated high levels of specificity and sensitivity particularly when compared to urinary PSA. There was a significant decrease in urinary MSMB with the high risk allele compared to the low risk allele.

Hayley Whitaker, Ph.D., the lead author, said, "Microseminoprotein-beta (MSMB), is easy to detect because it is found in urine and would potentially be a very simple test to carry out on men to identify those most at risk". The study was published on line on October 13, 2010, in the open access journal from the Public Library of Science, PLoS One.

Related Links:
Institute of Cancer Research



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Platelet Function Analyzer
PL-12
Automated Clinical Chemistry Analyzer
Envoy 500+
POC Immunoassay Analyzer
Procise DX
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Signatera uses ctDNA analysis to identify residual tumor-derived genetic material after definitive treatment (image credit: Adobe Stock)

Blood-Based MRD Test Predicts Recurrence Risk After Lung Cancer Surgery

Assessing recurrence risk after surgery for early-stage non-small cell lung cancer remains challenging, complicating adjuvant therapy and surveillance decisions. Blood-based molecular residual disease... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Type 1 diabetes affects more than 9 million people worldwide and can begin years before symptoms appear, making early identification of at-risk children difficult (Image Credit: iStock)

Early-Life Gut Microbiome Changes May Help Assess Type 1 Diabetes Risk

Type 1 diabetes (T1D) affects more than 9 million people worldwide, including 1.8 million children and adolescents, and often begins years before symptoms appear. Early identification of children who are... Read more

Pathology

view channel
Image: A new study demonstrates that vascular features in colorectal tumors could serve as prognostic biomarkers of disease outcome. (Image Credit: iStock)

Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival

Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Central to the collaboration is the Enhanced Liver Fibrosis (ELF) test, a noninvasive blood test authorized in the U.S. to assess disease progression risk in patients with advanced fibrosis due to MASH and support patient management decisions. (Photo courtesy of Siemens Healthineers)

Siemens Healthineers and Novo Collaborate to Expand Access to Noninvasive Liver Testing

Metabolic dysfunction‑associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction‑associated steatohepatitis (MASH), affect millions and are linked to obesity, type 2 diabetes,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.